DK3104838T3 - Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf - Google Patents
Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf Download PDFInfo
- Publication number
- DK3104838T3 DK3104838T3 DK15707019.4T DK15707019T DK3104838T3 DK 3104838 T3 DK3104838 T3 DK 3104838T3 DK 15707019 T DK15707019 T DK 15707019T DK 3104838 T3 DK3104838 T3 DK 3104838T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic
- preparation
- methods
- nanoparticles
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461939363P | 2014-02-13 | 2014-02-13 | |
| PCT/US2015/015887 WO2015123562A1 (en) | 2014-02-13 | 2015-02-13 | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3104838T3 true DK3104838T3 (da) | 2020-02-24 |
Family
ID=52595474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15707019.4T DK3104838T3 (da) | 2014-02-13 | 2015-02-13 | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10080723B2 (enExample) |
| EP (1) | EP3104838B1 (enExample) |
| JP (1) | JP6573895B2 (enExample) |
| CA (1) | CA2939261C (enExample) |
| DK (1) | DK3104838T3 (enExample) |
| ES (1) | ES2770733T3 (enExample) |
| HU (1) | HUE047934T2 (enExample) |
| PL (1) | PL3104838T3 (enExample) |
| PT (1) | PT3104838T (enExample) |
| SI (1) | SI3104838T1 (enExample) |
| WO (1) | WO2015123562A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3104838T3 (da) | 2014-02-13 | 2020-02-24 | Pfizer | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
| WO2015200054A2 (en) | 2014-06-24 | 2015-12-30 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| BR112018003110A2 (pt) * | 2015-08-21 | 2018-09-25 | Pfizer | nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos |
| EP3432864B1 (en) * | 2016-03-22 | 2020-05-06 | Pfizer Inc | Process for preparing therapeutic nanoparticles |
| WO2018208993A1 (en) * | 2017-05-09 | 2018-11-15 | Dignity Health | Drug delivery composition and method of fabrication |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| JP2021501753A (ja) * | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿 |
| EP3784705A4 (en) * | 2018-04-23 | 2022-03-02 | Graybug Vision, Inc. | IMPROVED CONTINUOUS PRODUCTION OF MICROPARTICLES |
| TWI787523B (zh) | 2018-06-15 | 2022-12-21 | 漢達生技醫藥股份有限公司 | 達沙替尼十二烷基硫酸鹽之結晶 |
| WO2020018890A1 (en) | 2018-07-19 | 2020-01-23 | Prudhomme Robert K | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| US20260199517A1 (en) * | 2022-11-18 | 2026-07-16 | Haima Therapeutics, Llc | Lyophilization buffers for peptide-decorated liposomes |
| KR20250136810A (ko) | 2023-01-31 | 2025-09-16 | 한다 온콜로지, 엘엘씨 | 개선된 카보잔티닙 조성물 및 사용 방법 |
| US20260108582A1 (en) * | 2024-10-23 | 2026-04-23 | Finitus, LLC | Compositions and methods for intranasal delivery of carnosine for treatment of neurodegenerative diseases and disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6869884B2 (en) * | 2002-08-22 | 2005-03-22 | Chartered Semiconductor Manufacturing Ltd. | Process to reduce substrate effects by forming channels under inductor devices and around analog blocks |
| AU2004259209A1 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| BR112015005878A2 (pt) * | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas |
| HUE043998T2 (hu) | 2012-09-17 | 2019-09-30 | Pfizer | Eljárás terápiás nanorészecskék elõállítására |
| HUE034490T2 (en) * | 2013-09-16 | 2018-02-28 | Astrazeneca Ab | Therapeutic polymer nanoparticles and methods for their preparation and use |
| DK3104838T3 (da) | 2014-02-13 | 2020-02-24 | Pfizer | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf |
| EP3116547B1 (en) | 2014-03-14 | 2019-06-05 | Pfizer Inc | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
-
2015
- 2015-02-13 DK DK15707019.4T patent/DK3104838T3/da active
- 2015-02-13 ES ES15707019T patent/ES2770733T3/es active Active
- 2015-02-13 PT PT157070194T patent/PT3104838T/pt unknown
- 2015-02-13 EP EP15707019.4A patent/EP3104838B1/en active Active
- 2015-02-13 SI SI201531085T patent/SI3104838T1/sl unknown
- 2015-02-13 JP JP2016551767A patent/JP6573895B2/ja not_active Expired - Fee Related
- 2015-02-13 WO PCT/US2015/015887 patent/WO2015123562A1/en not_active Ceased
- 2015-02-13 CA CA2939261A patent/CA2939261C/en active Active
- 2015-02-13 US US15/118,737 patent/US10080723B2/en active Active
- 2015-02-13 PL PL15707019T patent/PL3104838T3/pl unknown
- 2015-02-13 HU HUE15707019A patent/HUE047934T2/hu unknown
-
2018
- 2018-09-07 US US16/124,605 patent/US10583092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2770733T3 (es) | 2020-07-02 |
| US20170042828A1 (en) | 2017-02-16 |
| US10080723B2 (en) | 2018-09-25 |
| EP3104838A1 (en) | 2016-12-21 |
| PT3104838T (pt) | 2020-02-14 |
| JP6573895B2 (ja) | 2019-09-11 |
| PL3104838T3 (pl) | 2020-07-13 |
| JP2017505800A (ja) | 2017-02-23 |
| EP3104838B1 (en) | 2020-01-01 |
| US20190111004A1 (en) | 2019-04-18 |
| SI3104838T1 (sl) | 2020-04-30 |
| CA2939261A1 (en) | 2015-08-20 |
| WO2015123562A1 (en) | 2015-08-20 |
| US10583092B2 (en) | 2020-03-10 |
| HUE047934T2 (hu) | 2020-05-28 |
| CA2939261C (en) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3511019T3 (da) | Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf | |
| IL258931A (en) | Therapeutic compounds and methods | |
| IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| IL252532A0 (en) | Polycyclic carbamoylpyridone compounds and their pharmaceutical use | |
| IL247777B (en) | Ablation catheter and ablation apparatus | |
| DK3212255T3 (da) | Selvorienterende sprøjte og sprøjtegrænseflade | |
| IL249370A0 (en) | Fap-enabled medical substances and related uses | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| DK3209308T3 (da) | Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf | |
| SG10201500986TA (en) | Catheter devices and related methods | |
| HUE040395T2 (hu) | Ápolóeszköz és eljárás | |
| DK3117777T3 (da) | Spredningstomografifremgangsmåde og spredningstomografianordning | |
| GB201404470D0 (en) | Therapeutic methods and materials | |
| HUE047934T2 (hu) | Terápiás szert tartalmazó terápiás nanorészecskék, ezek elõállítása és alkalmazása | |
| IL283335B (en) | Dihydropyrimidine-2-one compounds and their medical use | |
| IL247325A0 (en) | Therapeutic methods using noribogaine and related compounds | |
| DK3114118T3 (da) | p-SUBSTITUEREDE ASYMMETRISKE URINSTOFFER OG MEDICINSK ANVENDELSE DERAF | |
| PL3129398T3 (pl) | Nowe środki medyczne i ich zastosowanie | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| DK3094338T3 (da) | Test og lægemiddel | |
| IL251930B (en) | Benzylhydroxy derivatives, their preparation and medical uses | |
| GB201416899D0 (en) | Medical devices and related methods | |
| GB201410387D0 (en) | Compounds and their therapeutic use | |
| GB201403496D0 (en) | Compounds and their therapeutic use |